BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32125253)

  • 1. Axillary Nodal Burden Assessed with Pretreatment Breast MRI Is Associated with Failed Sentinel Lymph Node Identification after Neoadjuvant Chemotherapy for Breast Cancer.
    Kim WH; Kim HJ; Park CS; Lee J; Park HY; Jung JH; Kim WW; Chae YS; Lee SJ; Kim SH
    Radiology; 2020 May; 295(2):275-282. PubMed ID: 32125253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Le-Petross HT; McCall LM; Hunt KK; Mittendorf EA; Ahrendt GM; Wilke LG; Ballman KV; Boughey JC
    AJR Am J Roentgenol; 2018 Mar; 210(3):669-676. PubMed ID: 29381381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study.
    Huang X; Shi Z; Mai J; Liu C; Liu C; Chen S; Lu H; Li Y; He B; Li J; Cun H; Han C; Chen X; Liang C; Liu Z
    Acad Radiol; 2023 Jul; 30(7):1257-1269. PubMed ID: 36280517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
    Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
    Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Boughey JC; Ballman KV; Hunt KK; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Le-Petross HT
    J Clin Oncol; 2015 Oct; 33(30):3386-93. PubMed ID: 25646192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.
    Al-Hattali S; Vinnicombe SJ; Gowdh NM; Evans A; Armstrong S; Adamson D; Purdie CA; Macaskill EJ
    Cancer Imaging; 2019 Dec; 19(1):91. PubMed ID: 31878958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer.
    Sun SX; Moseley TW; Kuerer HM; Yang WT
    AJR Am J Roentgenol; 2020 Feb; 214(2):249-258. PubMed ID: 31714846
    [No Abstract]   [Full Text] [Related]  

  • 11. Added Value of MRI for Invasive Breast Cancer including the Entire Axilla for Evaluation of High-Level or Advanced Axillary Lymph Node Metastasis in the Post-ACOSOG Z0011 Trial Era.
    Byon JH; Park YV; Yoon JH; Moon HJ; Kim EK; Kim MJ; You JK
    Radiology; 2021 Jul; 300(1):46-54. PubMed ID: 33904772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients.
    van Nijnatten TJA; Ploumen EH; Schipper RJ; Goorts B; Andriessen EH; Vanwetswinkel S; Schavemaker M; Nelemans P; de Vries B; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2016 Dec; 85(12):2288-2294. PubMed ID: 27842679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton TS; Kuerer HM; Bowling M; Hunt KK;
    Ann Surg; 2015 Mar; 261(3):547-52. PubMed ID: 25664534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.
    Moo TA; Jochelson MS; Zabor EC; Stempel M; Raiss M; Mamtani A; Tadros AB; El-Tamer M; Morrow M
    Ann Surg Oncol; 2019 Dec; 26(13):4238-4243. PubMed ID: 31583546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.